Daily Sepsis Research Analysis
Three papers advance sepsis science and methodology: a mechanistic eLife study identifies NINJ1-dependent plasma membrane rupture as a driver of inflammasome-linked coagulopathy; a PLoS Pathogens study reveals an MDSC–IDO1–tryptophan pathway suppressing T-cell immunity in hypervirulent Klebsiella bacteremia; and a systematic review shows major variability in mortality time frames across septic shock RCTs, underscoring the need for harmonized endpoints.
Summary
Three papers advance sepsis science and methodology: a mechanistic eLife study identifies NINJ1-dependent plasma membrane rupture as a driver of inflammasome-linked coagulopathy; a PLoS Pathogens study reveals an MDSC–IDO1–tryptophan pathway suppressing T-cell immunity in hypervirulent Klebsiella bacteremia; and a systematic review shows major variability in mortality time frames across septic shock RCTs, underscoring the need for harmonized endpoints.
Research Themes
- Immunothrombosis and pyroptosis mechanisms in sepsis
- Host immunosuppression via MDSCs and tryptophan metabolism (IDO1)
- Trial methodology and endpoint harmonization in septic shock
Selected Articles
1. Inhibiting NINJ1-dependent plasma membrane rupture protects against inflammasome-induced blood coagulation and inflammation.
This mechanistic study shows that NINJ1-mediated plasma membrane rupture is a key step linking inflammasome activation to the release of procoagulant TF-positive microvesicles, driving coagulopathy and inflammation. Genetic haploinsufficiency or glycine inhibition of NINJ1 reduced microvesicle and cytokine release and partially protected against flagellin-induced coagulopathy and death.
Impact: Identifies NINJ1-dependent membrane rupture as a tractable node in immunothrombosis, providing a new target for mitigating sepsis-associated coagulopathy and inflammation.
Clinical Implications: While preclinical, targeting NINJ1 or downstream membrane rupture may complement anticoagulation and anti-inflammatory strategies in sepsis/COVID coagulopathy. Development of selective NINJ1 inhibitors and biomarker-guided trials are warranted.
Key Findings
- NINJ1 promotes release of TF-positive procoagulant microvesicles during pyroptosis.
- NINJ1 haploinsufficiency or glycine inhibition reduces microvesicle and cytokine release.
- Inhibition of NINJ1-dependent membrane rupture partially protects against flagellin-induced coagulopathy and lethality.
Methodological Strengths
- Convergent genetic (haploinsufficiency) and pharmacologic (glycine) perturbations of NINJ1.
- In vivo protection data linking mechanistic pathway to coagulopathy and survival.
Limitations
- Preclinical mouse models; human validation is lacking.
- Glycine is a non-specific inhibitor; selective NINJ1 inhibitors were not tested.
Future Directions: Develop selective NINJ1 inhibitors; validate NINJ1/PMR biomarkers in human sepsis; test efficacy in diverse infectious models and coagulopathy phenotypes.
Systemic blood coagulation accompanies inflammation during severe infections like sepsis and COVID. We previously established a link between coagulopathy and pyroptosis, a vital defense mechanism against infection. During pyroptosis, the formation of gasdermin-D (GSDMD) pores on the plasma membrane leads to the release of tissue factor (TF)-positive microvesicles (MVs) that are procoagulant. Mice lacking GSDMD release fewer of these procoagulant MVs. However, the specific mechanisms coupling the activation of GSDMD to MV release remain unclear. Plasma membrane rupture (PMR) in pyroptosis was recently reported to be actively mediated by the transmembrane protein Ninjurin-1 (NINJ1). Here, we show that NINJ1 promotes procoagulant MV release during pyroptosis. Haploinsufficiency or glycine inhibition of NINJ1 limited the release of procoagulant MVs and inflammatory cytokines, and partially protected against blood coagulation and lethality triggered by bacterial flagellin. Our findings suggest a crucial role for NINJ1-dependent PMR in inflammasome-induced blood coagulation and inflammation.
2. Myeloid-derived suppressor cell inhibits T-cell-based defense against Klebsiella pneumoniae infection via IDO1 production.
In hypervirulent K. pneumoniae bacteremia, MDSCs suppress T-cell proliferation via an IDO1-driven tryptophan–kynurenine pathway, causing lymphopenia and weakened antibacterial responses. Genetic deletion or pharmacologic inhibition of IDO1 restored T-cell responses, nominating IDO1 as an immunotherapeutic target.
Impact: Links metabolic rewiring (tryptophan–kynurenine) to MDSC-mediated T-cell suppression in hvKp sepsis and demonstrates targetability with IDO1 inhibition.
Clinical Implications: Adjunctive IDO1 inhibition could enhance T-cell immunity in severe Gram-negative sepsis, particularly hvKp. Monitoring lymphopenia and tryptophan–kynurenine markers may guide host-directed therapies.
Key Findings
- hvKp infection induces lymphopenia via impaired T-cell proliferation and apoptosis.
- MDSCs infiltrate infected lungs and suppress T-cell proliferation through IDO1-driven tryptophan metabolism.
- L-kynurenine inhibits T-cell proliferation and induces apoptosis ex vivo; IDO1 knockout or 1-MT inhibition enhances T-cell responses in vivo.
Methodological Strengths
- Single-cell RNA-seq combined with in vivo bacteremia models for mechanistic mapping.
- Genetic (Ido1 knockout) and pharmacologic (1-MT) interventions providing convergent evidence.
Limitations
- Preclinical mouse model; clinical validation in humans is needed.
- Specificity and translational dosing of 1-MT may limit direct clinical applicability.
Future Directions: Assess IDO1 inhibitors and MDSC-targeted strategies in clinical sepsis; define biomarkers (kynurenine/tryptophan ratios, MDSC signatures) to stratify patients for host-directed therapy.
Klebsiella pneumoniae (Kp) is responsible for a wide range of infections, including pneumonia, sepsis, and urinary tract infections. However, the treatment options are limited due to the continuous evolution of drug-resistant and hypervirulent variants. It is crucial to investigate the mechanisms behind the high mortality rate of hypervirulent Kp (hvKp) strains to develop new strategies for preventing hvKp from evading the host's defenses and improving treatment effectiveness for these fatal infections. In this study, we used a hvKp-induced mouse bacteremia model and performed single-cell RNA sequencing to investigate the effects of hvKp infection. Our findings demonstrated that hvKp infection led to a decrease in lymphocytes (lymphopenia), attributed to impaired proliferation and apoptosis. The infiltration of myeloid-derived suppressor cells (MDSCs) in the infected lungs was confirmed to suppress T cell proliferation, leading to lymphopenia. We further identified that hvKp promotes tryptophan metabolism in infected lungs, enhancing the immunosuppressive activity of MDSCs by inducing the production of the enzyme IDO1. Our ex vivo inhibition experiment revealed that L-kynurenine, a product of tryptophan metabolism, inhibits T-cell proliferation and induces T-cell apoptosis, further suppressing T-cell mediated responses against bacteria. Importantly, when we knocked out the Ido1 gene or inhibited IDO1 expression using a specific inhibitor 1-MT in mice, we observed a significant enhancement in T-cell mediated responses against hvKp. These findings highlight the crucial role of MDSCs in hvKp-induced bacteremia and suggest a promising immunotherapeutic approach by inhibiting IDO1 production to combat infectious diseases.
3. Mortality time frame variability in septic shock clinical trials: A systematic review.
Across 132 septic shock RCTs, mortality endpoints were highly heterogeneous with 15 unique time frames; 28-day mortality was most common (74%), but hospital, ICU, and 90-day mortality were also frequently used. Such variability risks biased effect estimates and complicates meta-analyses, calling for consensus on standardized mortality time frames.
Impact: By quantifying endpoint heterogeneity, this review identifies a key barrier to evidence synthesis and trial comparability in septic shock and motivates consensus reporting standards.
Clinical Implications: Standardizing mortality time frames (e.g., 28 and 90 days) would improve comparability of septic shock trials, support guideline development, and enhance meta-analytic power.
Key Findings
- Among 132 septic shock RCTs, 234 mortality endpoints included 15 unique time frames.
- 28-day mortality was most frequently reported (74%), followed by hospital, ICU, and 90-day mortality.
- Temporal/geographic patterns exist; combined hospital+ICU mortality reporting decreased from 2008–2013 to 2014–2019 (P=0.043).
Methodological Strengths
- Comprehensive multi-database systematic search and clear inclusion criteria.
- Quantitative characterization of endpoint heterogeneity across RCTs.
Limitations
- No meta-analysis; potential selection bias from reported endpoints.
- Does not test how differing endpoints alter treatment effect estimates within specific trials.
Future Directions: Develop and adopt consensus core outcome sets (e.g., 28- and 90-day mortality) and harmonized statistical plans to enable robust comparisons and meta-analyses.
OBJECTIVE: We sought to delineate the mortality outcome time frames reported in septic shock randomized control trials (RCTs). DESIGN: Systematic review of PubMed, EMBASE, and the Cochrane Database of Systematic Reviews. SETTING: Intensive care units. PARTICIPANTS: Studies that included adult patients with septic shock. INTERVENTIONS: Any type of intervention. MAIN VARIABLES OF INTEREST: Information about the study, specific patient population, type of study intervention, specific intervention, and number of patients. Mortality time frames were analyzed for geographical differences and changes over time. RESULTS: The search yielded 2660 unique citations. After screening, 132 eligible studies were identified. A total of 234 mortality time frames were collected from the included studies, of which 15 timeframes were unique. The most frequently reported time frame was 28-day mortality (n = 98, 74% of trials), followed by hospital mortality (n = 35, 27%), ICU mortality (n = 30, 23%), and 90-day mortality (n = 29, 22%). The most reported mortality time frame was 28 days in studies from every continent except Africa. The studies published between 2008 and 2013 (25%) more frequently reported hospital and ICU mortality combination than studies published between 2014 and 2019 (11.4%) (P = 0.043). CONCLUSIONS: There was considerable variability in the mortality time frames reported in ICU-based septic shock trials. This variability may lead to under or overestimation of the problem, overlooking the effectiveness of the interventions studied, and further limiting the application of trials and their pooling in meta-analyses. A consensus regarding time frame reporting in septic shock trials is long overdue.